Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback